Novo Nordisk A/S (NYSE:NVO) Announces Quarterly Earnings Results

Novo Nordisk A/S (NYSE:NVO) issued its quarterly earnings results on Tuesday. The company reported $0.96 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.77 by $0.19, Zacks reports. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%.

Novo Nordisk A/S Stock Performance

Shares of NVO traded down $3.31 during trading hours on Tuesday, hitting $43.78. The stock had a trading volume of 22,720,725 shares, compared to its average volume of 18,053,473. The firm has a 50-day moving average price of $46.96 and a 200 day moving average price of $45.32. Novo Nordisk A/S has a fifty-two week low of $35.12 and a fifty-two week high of $64.16. The firm has a market capitalization of $195.46 billion, a price-to-earnings ratio of 10.34, a PEG ratio of 4.30 and a beta of 0.76. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.56 and a current ratio of 0.79.

Novo Nordisk A/S News Summary

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo Nordisk reported progress on its previously announced DKK 15 billion share-repurchase program. Continued buybacks can support earnings per share and signal management confidence in the stock’s valuation. Novo Nordisk Details Progress in DKK 15 Billion Share Buyback Programme
• Positive Sentiment: The company is partnering with H1 to expand AI-driven clinical development, potentially improving trial design, execution and data analysis. The initiative is strategically positive but is unlikely to materially affect near-term revenue. H1 Partners with Novo Nordisk to Scale AI-Driven Clinical Development
• Neutral Sentiment: Chief Executive Mike Doustdar is emphasizing risk-taking and the potential of Novo Nordisk’s weight-loss pill and newer medicines. The strategy could help the company regain momentum against Eli Lilly, but investors will want evidence of successful launches and stronger growth. Arrogance kills: Novo chief injects risk-taking into Ozempic maker
• Negative Sentiment: Novo Nordisk’s experimental heart drug ziltivekimab failed to meet the primary endpoint in the Phase 3 ZEUS trial. The setback undermines hopes of diversifying beyond GLP-1 therapies and has increased scrutiny of the company’s development pipeline. Novo Nordisk shares in hot water after disappointing trial
• Negative Sentiment: Citi maintained a Neutral rating, saying the selloff after the trial failure may have been excessive but citing persistent risks from obesity-drug pricing pressure, slowing injectable GLP-1 momentum and intense competition from Eli Lilly. Citi says Novo selloff overdone but GLP-1 worries keep it on the sidelines

Institutional Investors Weigh In On Novo Nordisk A/S

A number of institutional investors have recently modified their holdings of the business. Loomis Sayles & Co. L P increased its holdings in Novo Nordisk A/S by 6.0% in the 4th quarter. Loomis Sayles & Co. L P now owns 17,135,384 shares of the company’s stock worth $871,848,000 after acquiring an additional 969,916 shares in the last quarter. Morgan Stanley raised its position in shares of Novo Nordisk A/S by 3.5% during the 4th quarter. Morgan Stanley now owns 12,842,089 shares of the company’s stock worth $653,406,000 after purchasing an additional 428,660 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its stake in Novo Nordisk A/S by 99.7% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 9,688,262 shares of the company’s stock valued at $492,940,000 after buying an additional 4,836,285 shares in the last quarter. State Street Corp boosted its holdings in Novo Nordisk A/S by 1.0% in the 3rd quarter. State Street Corp now owns 6,106,836 shares of the company’s stock worth $340,125,000 after buying an additional 59,153 shares during the last quarter. Finally, Boston Partners purchased a new position in shares of Novo Nordisk A/S in the third quarter valued at approximately $310,199,000. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages have weighed in on NVO. Zacks Research downgraded Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a report on Monday, July 13th. Wall Street Zen downgraded shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Saturday, June 20th. Citigroup reiterated a “neutral” rating on shares of Novo Nordisk A/S in a research note on Monday, July 20th. HSBC reissued a “hold” rating on shares of Novo Nordisk A/S in a research report on Monday, July 6th. Finally, Nordea Equity Research raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Friday, June 19th. Five research analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, Novo Nordisk A/S presently has an average rating of “Hold” and an average price target of $65.56.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.